美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Silexion Therapeutics Corp

1.11

-0.1400-11.20%

盘前：1.140.0300+2.70%08:09 EDT

成交量：59.72万

成交额：70.29万

市值：934.02万

市盈率：-0.91

高：1.26

开：1.23

低：1.11

收：1.25

数据加载中...

总览公司新闻公告

公司资料

公司名字：

Silexion Therapeutics Corp

交易所：

NASDAQ

成立时间：

2008

员工人数：

- -

公司地址：

The Goldyne Savad Institute of Gene Therapy,Hadassah Hebrew University Medical Center,Jerusalem,Israel

官网：

http://www.silexion.com

邮编：

9112001

电话：

传真：

972 2 643 0982

简介：

Silexion Therapeutics Corp是一家开曼群岛豁免公司。Silexion Therapeutics Ltd.是Biomotion Sciences的子公司。Silexion Therapeutics Ltd.是一家临床阶段、专注于肿瘤学的生物技术公司，致力于发现和开发KRAS驱动的癌症的专有疗法。Silexion的主要候选产品SIL-204B由局部给药的小干扰RNA或siRNA组成，采用缓释制剂，作为局部晚期胰腺癌患者的一线治疗，与标准护理化疗相结合。SIL-204B是继Silexion的第一代siRNA候选产品SIG12D-LODER（也称为Loder）的1期和2期临床试验之后的第二代siRNA候选产品。尽管未确定最大耐受剂量，但1期临床试验同时达到了主要和次要终点。在2期临床试验中，虽然没有达到所有患者的主要终点，但结果显示KRAS G12D/V突变患者的治疗组之间存在差异趋势，Loder组的总体生存期优势为9.3个月。关于2期临床试验中的次要安全性终点，达到了终点。对于次要疗效终点，未观察到统计学上的显著差异，也没有足够的数据进行评估。由于1期和2期试验的规模较小，它们没有提供统计学意义。

董事

名称

职位

Ilan Levin

Chairman of the Board, Director, Secretary and Chief Executive Officer

Craig Marshak

Director

Eric Brachfeld

Director

Michael Basch

Director

Ruth Alon

Director

股东

名称

职位

Ilan Levin

Chairman of the Board, Director, Secretary and Chief Executive Officer

Gil Maman

Chief Financial Officer

Dan Yalon

Advisor

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/SLXN/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.11,"timestamp":1742414400000,"preClose":1.25,"halted":0,"volume":597177,"hourTrading":{"tag":"盘前","latestPrice":1.14,"preClose":1.11,"latestTime":"08:09 EDT","volume":352,"amount":401.036416,"timestamp":1742472555441},"delay":0,"changeRate":-0.112,"change":-0.14,"floatShares":5231700,"shares":8414615,"eps":-1.215216,"lyrEps":0.386244,"amount":702857.2041350999,"amplitude":0.11848,"volumeRatio":0.28087234137056494,"dividePrice":0,"prevYearClose":2.01,"fiveDayClose":1.38,"twentyDayClose":0.9877},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5231700,"roa":"--","roe":"--","lyrEps":0.386244,"volumeRatio":0.28087234137056494,"shares":8414615,"dividePrice":0,"high":1.2581,"amplitude":0.11848,"preClose":1.25,"low":1.11,"week52Low":0.575,"pbRate":"--","week52High":122.0184,"institutionHeld":0,"latestPrice":1.11,"committee":0.695775,"eps":-1.215216,"divideRate":0,"volume":597177,"delay":0,"ttmEps":-1.215216,"open":1.23,"prevYearClose":2.01,"prevWeekClose":1.31,"prevMonthClose":1.07,"prevQuarterClose":2.01,"fiveDayClose":1.38,"twentyDayClose":0.9877,"sixtyDayClose":2.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1730520000000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":134350646,"yearFounded":2008,"address":"The Goldyne Savad Institute of Gene Therapy,Hadassah Hebrew University Medical Center,Jerusalem,Israel","zipCode":"9112001","officePhone":"972 2 674 3430","officeFax":"972 2 643 0982"},"stockCompanyDetail":{"websiteUrl":"http://www.silexion.com","stockEarnings":[{"period":"1week","weight":-0.1957},{"period":"1month","weight":0.0278},{"period":"3month","weight":-0.5413},{"period":"6month","weight":-0.8582},{"period":"1year","weight":-0.9889},{"period":"ytd","weight":-0.4478}],"compareEarnings":[{"period":"1week","weight":0.0148},{"period":"1month","weight":-0.0698},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.002},{"period":"1year","weight":0.0997},{"period":"ytd","weight":-0.0323}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Silexion Therapeutics Corp是一家开曼群岛豁免公司。Silexion Therapeutics Ltd.是Biomotion Sciences的子公司。Silexion Therapeutics Ltd.是一家临床阶段、专注于肿瘤学的生物技术公司，致力于发现和开发KRAS驱动的癌症的专有疗法。Silexion的主要候选产品SIL-204B由局部给药的小干扰RNA或siRNA组成，采用缓释制剂，作为局部晚期胰腺癌患者的一线治疗，与标准护理化疗相结合。SIL-204B是继Silexion的第一代siRNA候选产品SIG12D-LODER（也称为Loder）的1期和2期临床试验之后的第二代siRNA候选产品。尽管未确定最大耐受剂量，但1期临床试验同时达到了主要和次要终点。在2期临床试验中，虽然没有达到所有患者的主要终点，但结果显示KRAS G12D/V突变患者的治疗组之间存在差异趋势，Loder组的总体生存期优势为9.3个月。关于2期临床试验中的次要安全性终点，达到了终点。对于次要疗效终点，未观察到统计学上的显著差异，也没有足够的数据进行评估。由于1期和2期试验的规模较小，它们没有提供统计学意义。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.0087},{"month":2,"riseRate":0.75,"avgChangeRate":-0.104682},{"month":3,"riseRate":1,"avgChangeRate":0.016028},{"month":4,"riseRate":1,"avgChangeRate":0.008863},{"month":5,"riseRate":0.25,"avgChangeRate":-0.001105},{"month":6,"riseRate":0.5,"avgChangeRate":0.01089},{"month":7,"riseRate":1,"avgChangeRate":0.012186},{"month":8,"riseRate":0.5,"avgChangeRate":-0.219676},{"month":9,"riseRate":0.75,"avgChangeRate":-0.154717},{"month":10,"riseRate":0.5,"avgChangeRate":-0.107747},{"month":11,"riseRate":0.5,"avgChangeRate":0.013201},{"month":12,"riseRate":0.25,"avgChangeRate":-0.069674}],"exchange":"NASDAQ","name":"Silexion Therapeutics Corp","nameEN":"Silexion Therapeutics Corp"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":{"directors":[{"name":"Ilan Levin","position":"Chairman of the Board, Director, Secretary and Chief Executive Officer"},{"name":"Craig Marshak","position":"Director"},{"name":"Eric Brachfeld","position":"Director"},{"name":"Michael Basch","position":"Director"},{"name":"Ruth Alon","position":"Director"}],"executives":[{"name":"Ilan Levin","position":"Chairman of the Board, Director, Secretary and Chief Executive Officer"},{"name":"Gil Maman","position":"Chief Financial Officer"},{"name":"Dan Yalon","position":"Advisor"}]}}}